Prescription drug · ANDA
Lactulose NDC 18124-002
Lactulose 10 g/15mL · Solution · Oral, Rectal · Fresenius Kabi Austria GmbH
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 18124-002-16 | 18124000216 | 473 mL in 1 BOTTLE (18124-002-16)Marketed from Dec 10, 2012 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lactulose
- Generic name (nonproprietary)
- lactulose
- Active ingredients
- Lactulose — 10 g/15mL
- Dosage form
- Solution
- Route
- Oral, Rectal
- Labeler
- Fresenius Kabi Austria GmbH
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 090502
- Marketing start
- Listing expires
- Other FDA classes
- Acidifying Activity (Mechanism)Osmotic Activity (Mechanism)Stimulation Large Intestine Fluid/Electrolyte Secretion (Physiologic effect)
- Identifiers
- Product ID 18124-002_d95ab755-1c2e-4124-8ed7-075936257c25SPL ID d95ab755-1c2e-4124-8ed7-075936257c25SPL set ID a89835c9-8ce5-4627-8d7d-70ff175b2e07RxCUI 391937UNII 9U7D5QH5AE
- Pharmacologic class
- Osmotic Laxative
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N418124000216followed by a unit qualifier and the quantityPackage 18124-0002-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled stud…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 090502
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.